Generex Biotechnology Corporation (NASDAQ:GNBT) der neue PLAYER - 500 Beiträge pro Seite

[js200]

Ich bin der Meinung, hier geht noch was

Last Trade: 1.620 Change: 0.270 (+20.000%)
Previous Close: 1.350 Volume: 500,800
Bid: 1.560 Ask: 1.670
Today`s Open: 1.370 # of Trades: 510

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/18/2003 (13:02 ET) GNBT to Present Study This Weekend in Scotland - Knobias



07/17/2003 (12:21 ET) New 8-K just released for GNBT - Edgar



07/16/2003 (10:06 ET) Generex Biotechnology to Present at The 30th Annual Meeting & Exposition Of The Controlled Release Society, July 19 - 23, Glasgow, Scotland - PR Newswire



07/11/2003 (16:39 ET) New 8-K/A just released for GNBT - Edgar



07/07/2003 (17:39 ET) 8-K: GNBT Fires Deloitte & Touche & Hires BDO Dunwoody - Knobias



07/07/2003 (17:19 ET) New 8-K just released for GNBT - Edgar



06/26/2003 (16:07 ET) S-3: GNBT Registers Over 8m Shares of Common Stock - Knobias



06/26/2003 (15:29 ET) New S-3 just released for GNBT - Edgar



06/24/2003 (19:18 ET) GNBT: Short Interest UP 88.4% to 357.2K in Jun 2003 - Knobias



06/24/2003 (16:23 ET) CLOSER(-): Last 90 Min, GNBT Drops -10.31%; Vol +67% - Knobias



06/23/2003 (11:57 ET) Generex rallies on positive Oralin study results - AFX News Europe



06/23/2003 (11:57 ET) Generex rallies on positive Oralin study results - AFX News UK



06/23/2003 (11:56 ET) Generex rallies on positive Oralin study results - AFX News Asia



06/23/2003 (09:23 ET) PREMARKET: GNBT Reports Data From Oralin Studies - Knobias



06/23/2003 (09:01 ET) Generex Biotechnology Reports Details of Studies Presented at the Endocrine Society`s ENDO 2003, 85th Annual Meeting - PR Newswire


JS200

[js200]

GNBT to Present Study This Weekend in Scotland

Friday , July 18, 2003 13:02 ET

Generex Biotechnology Corporation (NASDAQ NM : GNBT) will present a study, "Breakthrough Pain Relief; RapidMist(TM) Fentanyl/Morphine Breakthrough Pain Management Systems," at the 30th Annual Meeting & Exposition of the Controlled Release Society in Glasgow, Scotland, July 19 - 23, 2003.


Misc Releated Info:
** Original Confirmation

JS200

[js200]

Generex Biotechnology to Present at The 30th Annual Meeting & Exposition Of The Controlled Release Society, July 19 - 23, Glasgow, Scotland

Wednesday, July 16, 2003 10:06 ET

TORONTO, Jul 16, 2003 /PRNewswire-FirstCall via COMTEX/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), a leader in the area of buccal drug delivery, announced today that it will be presenting a study at the 30th Annual Meeting & Exposition of the Controlled Release Society (CRS) in Glasgow, Scotland, July 19 - 23, 2003. The study, being presented as a poster presentation, is entitled "Breakthrough Pain Relief; RapidMist(TM) Fentanyl/Morphine Breakthrough Pain Management Systems".

The CRS is an international organization which serves 3,000 members from more than 50 countries. Two-thirds of the CRS membership represents industry and one-third represents academia and government. The CRS is a multi-disciplinary society dedicated to the science and technology of controlled release and delivery and promoting education. The science of controlled release has become a research discipline the future of which depends on a thorough understanding of the interactions between the delivery system and the biological or environmental barriers to delivery of active substances.

About Generex

Generex is engaged in the research and development of drug delivery systems and technology. To date, it has focused on developing a platform technology for the buccal delivery -- delivery to the oral cavity for absorption through the inner mouth mucosa -- of drugs that historically have been administered only by injection. Generex`s buccal delivery technology has application to a large number of drugs.

This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward- looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


CONTACT:
Shayne Gilliatt
Generex Biotechnology Corporation
800-391-6755; 416-364-2551

Matthew Henderson
CEOcast, Inc.
212-732-4300
[e-mail]


SOURCE Generex Biotechnology Corporation


CONTACT: Shayne Gilliatt of Generex Biotechnology Corporation,
1-800-391-6755 or [phone]; or Matthew Henderson of CEOcast, Inc.
[phone], [e-mail], for Generex Biotechnology
Corporation
(GNBT)

http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: Ontario
Scotland
INDUSTRY KEYWORD: MTC
BIO
HEA


STOCK SYMBOLS: [(gnbt)]


JS200

[js200]

.
http://www.investtech.com/nasdaq/ana/gnbt.htm



JS200

[Huppfeld]

Ein bisschen heftig, dein pushen, aber im Grunde stimme ich dir zu; bin seit 5 Jahre Aktionär. Wir Beiden dürften hier zu Lande die Einzigen sein. Du hast nur zu erwähnen vergessen, dass der Kurs in Hypezeiten schon bei 24 $ stand.

[BrauchGeld]

#6

Ne hier ist noch ein Generex Aktionär

[tasmandevil]

Hier auch noch.
Gibt es irgendwelche News bezüglich Oralin ?
Wenn das Teil einschlägt müßte doch die Post abgehen.

tasmandevil